Behavioral and Environmental Factors Contributing to the Development and Progression of Congestive Heart Failure

Journal of Heart and Lung Transplantation

Volumn 19, Issue 8, 2000, Pages

  Olivari, Maria Teresa ^a  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; CARDIOTOXIN; COCAINE;

ALCOHOL ABUSE; BEHAVIOR; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE COURSE; ENVIRONMENTAL FACTOR; HEREDITY; HYPERTENSION; OBESITY; PRIORITY JOURNAL; REVIEW;

EID: 0034632641     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1053-2498(99)00106-0     Document Type: Article

References (85)

1. Kelder SH, Perry CL, Klepp KI. Longitudinal tracking of adolescent smoking, physical activity and food choice behaviors. Am J Public Health 1994;84:1121-6.
2. Colucci WS, Packer M, Bristow MR, et al for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-6.
3. Pfeffer MA, Braunwald E, Moyé LA, et al on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-77.
4. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
5. Vinson JM, Rich MW, Sperry JC, Shah AS, McNamara T. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc 1990;38:1290-5.
6. Dracup K, Baker DW, Dunbar SB, et al. Management of heart failure. II. Counseling, education, and lifestyle modifications. JAMA 1994;272:1442-6.
7. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-5.
8. West JA, Miller NH, Parker KM, et al. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiol 1997;79:58-63.
9. Weiner H. Stressful experience and cardiorespiratory disorders. Circulation 1991;83(suppl II):II-2-8.
10. Lown B. Sudden cardiac death: biobehavioral perspective. Circulation 1987;76(suppl I):I-186-95.
11. Kubzansky LD, Kawachi I, Spiro A, Weiss ST, Vokonas PS, Sparrow D. Is worrying bad for your heart? A prospective study of worry and coronary artery disease in the normative aging study. Circulation 1997;95:818-24.
12. Meerson FZ. Primary stress damage to the heart. In Nagano M, Takeda N, Dhalla HS eds. The cardiomyopathic heart. Raven Press, New York, 1994:401-18.
13. Cebelin MS, Hirsch CS. Human stress cardiomyopathy. Myocardial lesions in victims of homicidal assaults without internal injuries. Hum Pathol 1980;11:123-32.
14. Kahn JP, Gorman JM, King DL, Fyer AJ, Liebowitz MR, Klein DF. Cardiac left ventricular hypertrophy and chamber dilatation in panic disorder patients: implications for idiopathic dilated cardiomyopathy. Psychiatry Res 1990;32:55-61.
15. Kahn JP, Drusin RE, Klein DF. Idiopathic cardiomyopathy and panic disorder: clinical association in cardiac transplant candidates. Am J Psychiatry 1987;144:1327-30.
16. Peters RW, McQuillan S, Resnick SK, Gold MR. Increased Monday incidence of life-threatening ventricular arrhythmias. Experience with a third-generation implantable defibrillator. Circulation 1996;94:1346-9.
17. Schnall PL, Pieper C, Schwartz JE, et al. The relationship between "job strain," workplace diastolic blood pressure and left ventricular mass index. Results of a case-control study. JAMA 1990;263:1929-35.
18. Giannuzzi P, Shabetai R, Imparato A, et al. Effects of mental exercise in patients with dilated cardiomyopathy and congestive heart failure. An echocardiographic doppler study. Circulation 1991;83(suppl II):II-155-65.
19. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The lifestyle heart trial. Lancet 1990;336:129-33.
20. Coats A, Adamopoulos S, Radaelli A, et al. Controlled trial of physical training in chronic heart failure. Circulation 1992;85:2119-31.
21. Belardinelli R, Georgiou D, Scocco V, Barstow TJ, Purcaro A. Low intensity exercise training in patients with chronic heart failure. J Am Coll Cardiol 1995;26:975-82.
22. Giannuzzi P, Tavazzi L, Temporelli PL, et al. Long-term physical training and left ventricular remodeling after anterior myocardial infarction: results of the exercise in anterior myocardial infarction (EAMI) trial. J Am Coll Cardiol 1993;22:1821-9.
23. WHO/ISFC (World Health Organization/International Society and Federation of Cardiology) Report of the Task Force on the definition and classification of cardiomyopathies. Br Heart J 1980;44:672-3.
24. Urbano-Marquez A, Estruch R, Navarro-Lopez F, Grau JM, Mont L, Rubin E. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989;320:409-15.
25. Dancy M, Bland JM, Leech G, Gaitonde MK, Maxwell JD. Preclinical left ventricular abnormalities in alcoholics are independent of nutritional status, cirrhosis, and cigarette smoking. Lancet 1985;1:1122-5.
26. Wu S, White R, Wikman-Coffelt J, et al. The preventive effect of verapamil on ethanol-induced cardiac depression: phosphorus-31 nuclear magnetic resonance and high-pressure liquid chromatographic studies of hamsters. Circulation 1987;75:1058-64.
27. Thomas AP, Rozanski DJ, Renard DC, Rubin E. Effects of ethanol on the contractile function of the heart: a review. Alcohol Clin Exp Res 1994;18:121-31.
28. Randin D, Vollenweider P, Tappy L, Jéquier E, Nicod P, Scherrer U. Suppression of alcohol-induced hypertension by dexamethasone. N Engl J Med 1995;332:1733-7.
29. Kupari M, Koskinen P. Comparison of cardiotoxicity of ethanol in women versus men. Am J Cardiol 1992;70:645-9.
30. Gavazzi A, De Maria R, Renosto G, et al. The spectrum of left ventricular size in dilated cardiomyopathy: clinical correlates and prognostic implications. Am Heart J 1993;125: 410-22.
31. Demakis JG, Proskey A, Rahimtoola SH, et al. The natural course of alcoholic cardiomyopathy. Ann Intern Med 1974; 80:293-7.
32. Prazak P, Pfisterer M, Osswald S, Buser P, Burkart F. Differences of disease progression in congestive heart failure due to alcoholic as compared to idiopathic dilated cardiomyopathy. Eur Heart J 1996;17:251-7.
33. Ballester M, Martí V, Carrió I, et al. Spectrum of alcohol- induced myocardial damage detected by Indium-111-labeled monoclonal antimyosin antibodies. J Am Coll Cardiol 1997; 29:160-7.
34. 111In monoclonal antimyosin antibodies. Circulation 1994; 89:2054-61.
35. La Vecchia L, Bedogni F, Bozzola L, Bevilacqua P, Ometto R, Vincenzi M. Prediction of recovery after abstinence in alcoholic cardiomyopathy: role of hemodynamic and morphometric parameters. Clin Cardiol 1996;19:45-50.
36. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among U.S. adults. The national health and nutrition examination surveys, 1960 to 1991. JAMA 1994;272:205-11.
37. White A, Nicolaas G, Foster K, Browne F, Carey S. Health Survey for England 1991. London, England: Her Majesty's Stationary Office; 1993.
38. Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol 1992;70:921-4.
39. de Divitiis O, Fazio S, Petitto M, Maddalena G, Contaldo F, Mancini M. Obesity and cardiac function. Circulation 1981; 64:477-82.
40. Zarich SW, Kowalchuk GJ, McGuire MP, Benotti PN, Mascioli EA, Nesto RW. Left ventricular filling abnormalities in asymptomatic morbid obesity. Am J Cardiol 1991;68: 377-81.
41. Scherrer U, Randin D, Tappy L, Vollenweider P, Jéquier E, Nicod P. Body fat and sympathetic nerve activity in healthy subjects. Circulation 1994;89:2634-40.
42. Young JB, Landsberg L. Stimulation of the sympathetic nervous system during sucrose feeding. Nature 1977;269: 615-7.
43. Berne C, Fagius J, Pollare T, Hjemdahl P. The sympathetic response to euglycaemic hyperinsulinaemia: evidence from microelectrode nerve recordings in healthy subjects. Diabetologia 1992;35:873-9.
44. Victor RG, Bertocci LA, Pryor SL, Nunally RL. Sympathetic nervous discharge is coupled to muscle cell pH during exercise in humans. J Clin Invest 1988;82:1301-5.
45. Virmani R, Robinowitz M, Smialek JE, Smyth DF. Cardiovascular effects of cocaine: an autopsy study of 40 patients. Am Heart J 1988;115:1068-76.
46. Peng SK, French WJ, Pelikan PCD. Direct cocaine cardiotoxicity demonstrated by endomyocardial biopsy. Arch Pathol Lab Med 1989;113:842-5.
47. Chakko S, Fernandez A, Mellman TA, Milanes FJ, Kessler KM, Myerburg RJ. Cardiac manifestations of cocaine abuse: a cross-sectional study of asymptomatic men with a history of long-term abuse of "crack" cocaine. J Am Coll Cardiol 1992;20:1168-74.
48. Brickner ME, Willard JE, Eichhorn EJ, Black J, Grayburn PA. Left ventricular hypertrophy associated with chronic cocaine abuse. Circulation 1991;84:1130-5.
49. Willens HJ, Chakko SC, Kessler KM. Cardiovascular manifestations of cocaine abuse. A case of recurrent dilated cardiomyopathy. Chest 1994;106:594-600.
50. Kloner RA, Hale S, Alker K, Rezkalla S. The effects of acute and chronic cocaine use on the heart. Circulation 1992;85: 407-19.
51. Tazelaar HD, Karch SB, Stephens BG, Billingham ME. Cocaine and the heart. Hum Pathol 1987;18:195-9.
52. Chokshi SK, Gal D, Whelton JA, Isner JM. Evidence that fetal distress in newborns of cocaine users is due to vascular spasm and may be attenuated by pre-treatment with diltiazem. Circulation 1989;80(suppl II):II-185 (abstract).
53. Lange RA, Cigarroa RG, Yancy CW, et al. Cocaine-induced coronary-artery vasoconstriction. N Engl J Med 1989;321: 1557-62.
54. Rezkalla SH, Mazza JJ, Kloner RA, Tillema V, Chang SH. Effects of cocaine on human platelets in healthy subjects. Am J Cardiol 1993;72:243-6.
55. Moliterno DJ, Lange RA, Gerard RD, Willard JE, Lackner C, Hillis LD. Influence of intranasal cocaine on plasma constituents associated with endogenous thrombosis and thrombolysis. Am J Med 1994;96:492-6.
56. Eichorn EJ, Demian SE, Alvarez LG, et al. Cocaine-induced alterations in prostaglandin production in rabbit aorta. J Am Coll Cardiol 1992;19:696-703.
57. Jacobs LJ. Reversible dilated cardiomyopathy induced by methamphetamine. Clin Cardiol 1989;12:725-7.
58. Combs AB, Acosta D. Toxic mechanisms of the heart: a review. Toxicol Path 1990;18:583-96.
59. Kantrowitz N, Bristow MR. Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis 1984;25:195-200.
60. Lee V, Randhawa AK, Singal PK. Adriamycin-induced myocardial dysfunction in vitro is mediated by free radicals. Am J Physiol 1991;261:H989-95.
61. Siveski-Ihshovic N, Kach N, Singal PK. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 1994;89:2829-35.
62. Bristow MR, Sageman WS, Scott RH, et al. Acute and chronic cardiovascular effects of doxorubicin in the dog: The cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol 1980;2:487-515.
63. Tong J, Ganguly PK, Singal PK. Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol 1991;260:H909-16.
64. Deyton LR, Walker RE, Kovacs JA, et al. Reversible cardiac dysfunction associated with interferon α therapy in AIDS patients with Kaposi's sarcoma. N Engl J Med 1989;321: 1246-9.
65. Cunningham SR, Dalzell GWN, McGirr P, Khan MM. Myocardial infarction and primary ventricular fibrillation after glue sniffing. Br Med J 1987;294:739-40.
66. McMeekin JD, Finegan BA. Reversible myocardial dysfunction following carbon monoxide poisoning. Can J Cardiol 1987;3:118-21.
67. Amital Y, Mines Y, Aker M, Goitein K. Scorpion sting in children. A review of 51 cases. Clin Pediatr 1985;24:136-40.
68. Morin Y, Tetu A, Mercier G. Québec beer-drinkers' cardiomyopathy: clinical and hemodynamic aspects. Ann NY Acad Sci 1969;156:566-76.
69. Shimon I, Almag S, Vered Z, et al. Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy. Am J Med 1995;98:485-90.
70. Singal PK, Kirshenbaum LA. A relative deficit in antioxidant reserve may contribute in cardiac failure. Can J Cardiol 1990;6:47-9.
71. Gupta M, Singal PK. Higher antioxidative capacity during chronic stable heart hypertrophy. Circ Res 1989;64:398-406.
72. Khaper N, Singal PK. Effects of afterload-reducing drugs on pathogenesis of antioxidant changes and congestive heart failure in rats. J Am Coll Cardiol 1997;29:856-61.
73. Palmer BF. Renal complications associated with use of nonsteroidal anti-inflammatory agents. J Investig Med 1995; 43:516-33.
74. Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996;276:1328-31.
75. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Adverse Experience Committee, Multi-center Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991;83:52-60.
76. Packer M, O'Connor CM, Ghali JK, et al for the Prospective Randomized Amlodipine Survival Evaluation Study Group: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-14.
77. Michels VV, Moll PP, Miller FA, et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med 1992;326: 77-82.
78. Honda Y, Yokota Y, Yokoyama M. Familial aggregation of dilated cardiomyopathy. Evaluation of clinical characteristics and prognosis. Jpn Circ J 1995;59:589-98.
79. Berko B, Swift M. X-linked dilated cardiomyopathy. N Engl J Med 1987;316:1186-91.
80. Mestroni L, Severini GM, Milasin J, et al. Molecular genetics of dilated cardiomyopathies. Eur Heart J 1995;16(Suppl O):5-9.
81. Bowles KR, Gajarki R, Porter P, et al. Gene mapping of familial autosomal dominant dilated cardiomyopathy to chromosome 10q21-23. J Clin Invest 1996;98:1355-60.
82. Milasin J, Muntoni F, Severini GM, et al. A point mutation in the 5′ splice site of the dystrophin gene first intron responsible for x-linked dilated cardiomyopathy. Hum Mol Genet 1996;5:73-9.
83. Hattori K, Ogawa T, Kondo T, et al. Cardiomyopathy with mitochondrial DNA mutations. Am Heart J 1991;121:866-9.
84. Caforio ALP, Goldman JH, Baig MK, Keeling PJ, Bottazzo GF, McKenna WJ. Organ-specific cardiac autoantibodies in dilated cardiomyopathy: an update. Eur Heart J 1995; 16(Suppl O):68-70.
85. Limas O. Cardiac autoantibodies in dilated cardiomyopathy. A pathogenetic role? Circulation 1997;95:1979-80.